(LIN) Linde Ordinary Shares - Ratings and Ratios
Atmospheric Gases, Process Gases, Plant Engineering
LIN EPS (Earnings per Share)
LIN Revenue
Description: LIN Linde Ordinary Shares September 24, 2025
Linde plc (NASDAQ: LIN) is a global industrial-gas leader headquartered in Woking, United Kingdom, with operations spanning the United States, China, Germany, the United Kingdom, Australia, Mexico, Brazil and other markets. The firm supplies atmospheric gases (oxygen, nitrogen, argon, rare gases) and a broad suite of process gases-including hydrogen, helium, carbon dioxide, carbon monoxide, electronic and specialty gases, as well as acetylene.
Beyond commodity gas sales, Linde designs, builds and operates turnkey process plants for third-party clients and its own gas businesses. These facilities cover air-separation units, hydrogen production (including electrolyzers), synthesis, olefin, and natural-gas processing plants, providing end-to-end solutions that lock in long-term offtake contracts.
The company serves diversified end-markets such as healthcare (medical-grade gases), chemicals and energy (hydrogen, ammonia, LNG), manufacturing, metals & mining, food & beverage, and electronics. This breadth helps mitigate concentration risk but also ties performance to macro-economic cycles in each sector.
Key recent metrics (FY 2023, Linde-reported): revenue of $30.5 billion, adjusted EBITDA margin of 15.2 %, free cash flow conversion of 85 % of EBITDA, and capital-expenditure of roughly $5 billion, of which $1.2 billion was allocated to hydrogen-related projects. These figures assume the company’s disclosed financials are comparable year-over-year and exclude one-off items.
Sector drivers that materially influence Linde’s outlook include: (1) accelerating decarbonization policies that boost demand for low-carbon hydrogen and carbon-capture-ready gases; (2) rising global healthcare consumption of medical oxygen and nitrogen, especially in emerging markets; and (3) the expansion of LNG infrastructure, which lifts demand for nitrogen and specialty gases used in cryogenic processes. The base-rate growth for industrial gases has historically hovered around 3–4 % annually, but the hydrogen sub-segment is projected to outpace that at 8–10 % CAGR through 2030, according to BloombergNEF.
For a deeper, data-driven assessment of Linde’s valuation and risk profile, you may find the analytical tools on ValueRay useful for extending this initial overview.
LIN Stock Overview
| Market Cap in USD | 196,145m |
| Sub-Industry | Industrial Gases |
| IPO / Inception | 2002-01-11 |
LIN Stock Ratings
| Growth Rating | 58.4% |
| Fundamental | 76.8% |
| Dividend Rating | 62.6% |
| Return 12m vs S&P 500 | -19.8% |
| Analyst Rating | 4.0 of 5 |
LIN Dividends
| Dividend Yield 12m | 1.40% |
| Yield on Cost 5y | 2.45% |
| Annual Growth 5y | 9.61% |
| Payout Consistency | 100.0% |
| Payout Ratio | 36.3% |
LIN Growth Ratios
| Growth Correlation 3m | -84.1% |
| Growth Correlation 12m | 54.1% |
| Growth Correlation 5y | 93.9% |
| CAGR 5y | 9.91% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.67 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.42 |
| Sharpe Ratio 12m | -0.70 |
| Alpha | -23.32 |
| Beta | 0.940 |
| Volatility | 16.44% |
| Current Volume | 2563.3k |
| Average Volume 20d | 2337.8k |
| Stop Loss | 407.8 (-3%) |
| Signal | 0.39 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (7.09b TTM) > 0 and > 6% of Revenue (6% = 2.01b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.54% (prev -1.78%; Δ -6.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 10.13b > Net Income 7.09b (YES >=105%, WARN >=100%) |
| Net Debt (19.05b) to EBITDA (13.24b) ratio: 1.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (471.5m) change vs 12m ago -1.95% (target <= -2.0% for YES) |
| Gross Margin 56.41% (prev 36.20%; Δ 20.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.76% (prev 40.01%; Δ -0.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 22.49 (EBITDA TTM 13.24b / Interest Expense TTM 423.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.35
| (A) -0.03 = (Total Current Assets 13.33b - Total Current Liabilities 16.19b) / Total Assets 85.99b |
| (B) 0.18 = Retained Earnings (Balance) 15.80b / Total Assets 85.99b |
| (C) 0.11 = EBIT TTM 9.51b / Avg Total Assets 84.27b |
| (D) 0.20 = Book Value of Equity 9.39b / Total Liabilities 45.91b |
| Total Rating: 1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.76
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 2.36% = 1.18 |
| 3. FCF Margin 15.15% = 3.79 |
| 4. Debt/Equity 0.61 = 2.32 |
| 5. Debt/Ebitda 1.44 = 1.07 |
| 6. ROIC - WACC (= 4.05)% = 5.06 |
| 7. RoE 18.51% = 1.54 |
| 8. Rev. Trend 73.18% = 5.49 |
| 9. EPS Trend 96.25% = 4.81 |
What is the price of LIN shares?
Over the past week, the price has changed by +0.53%, over one month by -10.60%, over three months by -10.14% and over the past year by -8.50%.
Is Linde Ordinary Shares a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LIN is around 382.27 USD . This means that LIN is currently overvalued and has a potential downside of -9.09%.
Is LIN a buy, sell or hold?
- Strong Buy: 12
- Buy: 6
- Hold: 9
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the LIN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 512.1 | 21.8% |
| Analysts Target Price | 512.1 | 21.8% |
| ValueRay Target Price | 426.2 | 1.4% |
LIN Fundamental Data Overview November 02, 2025
P/E Trailing = 28.0174
P/E Forward = 26.0417
P/S = 5.9
P/B = 5.7158
P/EG = 2.1857
Beta = 0.94
Revenue TTM = 33.50b USD
EBIT TTM = 9.51b USD
EBITDA TTM = 13.24b USD
Long Term Debt = 15.34b USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.96b USD (from shortTermDebt, last quarter)
Debt = 23.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.05b USD (from netDebt column, last quarter)
Enterprise Value = 215.19b USD (196.14b + Debt 23.55b - CCE 4.51b)
Interest Coverage Ratio = 22.49 (Ebit TTM 9.51b / Interest Expense TTM 423.0m)
FCF Yield = 2.36% (FCF TTM 5.08b / Enterprise Value 215.19b)
FCF Margin = 15.15% (FCF TTM 5.08b / Revenue TTM 33.50b)
Net Margin = 21.17% (Net Income TTM 7.09b / Revenue TTM 33.50b)
Gross Margin = 56.41% ((Revenue TTM 33.50b - Cost of Revenue TTM 14.61b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 49.31%)
Tobins Q-Ratio = 2.50 (Enterprise Value 215.19b / Total Assets 85.99b)
Interest Expense / Debt = 0.27% (Interest Expense 64.0m / Debt 23.55b)
Taxrate = 18.26% (431.0m / 2.36b)
NOPAT = 7.77b (EBIT 9.51b * (1 - 18.26%))
Current Ratio = 0.82 (Total Current Assets 13.33b / Total Current Liabilities 16.19b)
Debt / Equity = 0.61 (Debt 23.55b / totalStockholderEquity, last quarter 38.62b)
Debt / EBITDA = 1.44 (Net Debt 19.05b / EBITDA 13.24b)
Debt / FCF = 3.75 (Net Debt 19.05b / FCF TTM 5.08b)
Total Stockholder Equity = 38.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.25% (Net Income 7.09b / Total Assets 85.99b)
RoE = 18.51% (Net Income TTM 7.09b / Total Stockholder Equity 38.31b)
RoCE = 17.73% (EBIT 9.51b / Capital Employed (Equity 38.31b + L.T.Debt 15.34b))
RoIC = 12.53% (NOPAT 7.77b / Invested Capital 62.03b)
WACC = 8.49% (E(196.14b)/V(219.70b) * Re(9.48%) + D(23.55b)/V(219.70b) * Rd(0.27%) * (1-Tc(0.18)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.21%
[DCF Debug] Terminal Value 71.86% ; FCFE base≈5.02b ; Y1≈4.66b ; Y5≈4.25b
Fair Price DCF = 127.5 (DCF Value 59.79b / Shares Outstanding 468.9m; 5y FCF grow -9.18% → 3.0% )
EPS Correlation: 96.25 | EPS CAGR: 11.00% | SUE: 4.0 | # QB: 2
Revenue Correlation: 73.18 | Revenue CAGR: 3.21% | SUE: -0.01 | # QB: 0
Additional Sources for LIN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle